Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer

Prostate Cancer Clinical Trial

Official title: Assessing Bone Mineral Density as a Risk Factor for Early Clinically Significant Prostate Cancer

Status Completed

Clinical Trial Summary

RATIONALE: Measuring bone mineral density may help doctors predict whether prostate cancer will come back. It may also help the study of prostate cancer in the future.

PURPOSE: This clinical trial is studying whether bone mineral density affects cancer recurrence in patients with early stage prostate cancer.

Clinical Trial Description

OBJECTIVES:

• Determine bone mineral density (BMD) in patients with clinically significant early stage prostate cancer.

• Determine whether patients who have a higher level of BMD and have had a radical prostatectomy for cure are less likely to have an early relapse (i.e., less than 3 years) than those patients with a low level of BMD.

OUTLINE: This is a case-controlled study followed by a prospective, longitudinal, cohort study.

Patients undergo bone mineral density (BMD) measurements by dual-energy x-ray absorptiometry with a densitometer. Posteroanterior measurements of the total hip are also recorded.

Patients also undergo blood collection to examine markers that provide evidence of systemic disease.

Patients are followed every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study. ;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Osteoporosis
• Prostate Cancer
• Prostatic Neoplasms

• NCT number: NCT00176579
• Study type: Observational
• Source: Rutgers, The State University of New Jersey
• Status: Completed
• Phase: N/A
• Start date: June 2003
• Completion date: July 2008